A pivotal trial of EYLEA HD for treatment of retinal vein occlusion (RVO)
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal vein occlusion
- Focus Registrational; Therapeutic Use
Most Recent Events
- 09 Feb 2024 New trial record
- 02 Feb 2024 According to a Regeneron pharmaceuticals media release, the company plans to start this trial mid-2024 to enable FDA submission.